Should we really STOP treating patients with IgA nephropathy with steroids?

Locatelli, F and Del Vecchio, L and Ponticelli, C (2018) Should we really STOP treating patients with IgA nephropathy with steroids? Physiology International, 105 (2). pp. 101-109. ISSN 2498-602X

Preview

Text 2060.105.2018.2.10.pdf Download (87kB) | Preview

Abstract

IgA nephropathy (IgAN) is the most common primary glomerulonephritis all over the world. Once considered as a benign disease, today the scientific community is aware that a significant percentage of patients eventually progress to end-stage kidney disease (ESKD). The rate of progression is often very slow. Since 1980s, several therapeutic attempts have been made with steroids. Despite different molecules, doses, and lengths of treatment, the majority of uncontrolled and controlled studies found benefits in terms of proteinuria reduction and reduction of the risk of ESKD. This was obtained with reasonable safety and tolerability, especially when steroids are given at relatively low dose and for a period not exceeding 6 months. Recently, two randomized controlled trials have questioned the efficacy and safety of steroid therapy in IgAN. However, these trials have many drawbacks that are to be considered when interpreting the findings.

Actions (login required)

Edit Item